Clinical Trials Logo

BCG Vaccination clinical trials

View clinical trials related to BCG Vaccination.

Filter by:
  • None
  • Page 1

NCT ID: NCT04384614 Withdrawn - Covid 19 Clinical Trials

Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study

CONNAITRE
Start date: May 15, 2020
Phase:
Study type: Observational [Patient Registry]

Covid-19 In Tunisia: AN Observational Cross-Sectional Registry Study

NCT ID: NCT04347876 Recruiting - COVID-19 Clinical Trials

Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?

Start date: April 11, 2020
Phase:
Study type: Observational

There is no evidence that the Bacille Calmette-Guérin vaccine (BCG) protects people against infection with COVID-19 virus. Two clinical trials addressing this question are underway, and WHO will evaluate the evidence when it is available. In the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. WHO continues to recommend neonatal BCG vaccination in countries or settings with a high incidence of tuberculosis. There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown

NCT ID: NCT04064554 Completed - Tuberculosis Clinical Trials

Clinical Study to Evaluate Safety and Immunogenicity of Bacillus Calmette-Guerin (BCG) Delivery Via Novel Micronjet600 Device Compared to Those Via Conventional Needle

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate safety and immunogenicity of Bacillus Calmette-Guerin (BCG) delivery via Novel Micronjet600 device compared to those via conventional needle.

NCT ID: NCT02175420 Completed - BCG Vaccination Clinical Trials

Role of BCG as Booster Vaccination

Start date: July 2012
Phase: N/A
Study type: Interventional

The BCG (bacillus Calmette-Guerin) vaccine is used for the protection against tuberculosis. Apart from it's protective effect against tuberculosis BCG vaccine has been shown to have non-specific effects on the innate immune system and is in epidemiological studies associated with reduced mortality due to infectious diseases. Several studies have shown that BCG can boost the effect of other vaccines. The present study aims to investigate the boosting effect of BCG on the response to typhoid fever vaccine (TFV) and to assess the non-specific effects of BCG on the innate immune system at early timepoints by vaccinating volunteers with either TFV alone or BCG followed by TFV 14 days later. The study hypothesis is that when BCG is given 14 days before typhoid fever vaccine a better vaccination result in terms of antibody production will be accomplished against typhoid fever due to the effects of BCG on the innate immune system.